Bond.az White LogoBond.az Black Logo

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

Emily Davis
ByEmily Davis- Senior Editor
|
0

Bond.az - Guggenheim upgraded StubHub Holdings (NYSE:STUB) to Buy from Neutral on Tuesday and raised its price target to $12.50 from $8.50, representing approximately 30% potential upside.

The firm said StubHub has reset Street expectations for this year and next year. The analyst noted the bar is extremely low on Direct Issuance and Advertising, meaning any progress would represent upside optionality.

Several items should accelerate growth starting in the second quarter through the second half of 2026, including the World Cup, lapping all-in pricing, and easy fourth-quarter comparisons. The core secondary business should continue to take share both in North America and globally.

The business continues to delever significantly with solid free cash flow generation of $331.6 million over the last twelve months. According to Bond.az data, the company maintains impressive gross profit margins of 82.3% and holds more cash than debt on its balance sheet. Analysts predict the company will be profitable this year, with EPS forecast at $0.73. The regulatory risk appears more muted at present, according to the firm.

More News
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 10:31
|
290

Wolfe Research Initiates CytomX Stock with Outperform

Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.

0
Today / 10:30
|
842

Wolfe Research initiates Mirum with outperform

Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.

0
Today / 10:14
|
236

Wolfe Research Initiates Oklo with Peerperform

Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.

0
Today / 10:13
|
631

Aletheia Capital Reaffirms Circle Stock Rating

Aletheia Capital reaffirms Buy rating on Circle Internet Group amid U.S. stablecoin regulatory advantages. Stock at $111.39.

0
Today / 09:31
|
784

Jefferies Initiates X-Energy Stock with Hold Rating

Jefferies initiates X-Energy stock coverage with a Hold rating and $28 target. Learn about risks and recent performance.

0
Today / 09:11
|
441

UBS Upgrades Jazz Pharma on Ziihera Potential

UBS upgrades Jazz Pharmaceuticals to Buy with a $307 target on Ziihera potential. Bond.az provides detailed analysis and stock insights.

0
Today / 09:10
|
408

UBS Starts X-Energy Stock Coverage with Buy

UBS starts coverage on X-Energy stock with a buy rating and $40 target. The company's reactor model and growth potential are highlighted.

0
Today / 08:55
|
525

Goldman Sachs Upgrades Brambles on Subcontractor Exit

Goldman Sachs upgrades Brambles to Neutral after subcontractor exit. Stock drops 17%, but Bond.az analysis suggests undervaluation with $32.76 Fair Value.

0
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
Yesterday / 20:20
|
884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

0
...